Laferobion
In this article, you can read the instructions for using the drug Laferobion. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors specialists on the use of Laferobion in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Laferobion in the presence of existing structural analogues. Use for the treatment of herpes, hepatitis, influenza and other infectious diseases in adults, children, as well as during pregnancy and lactation. Composition of the preparation.
Laferobion - recombinant human interferon, which corresponds to Interferon a-2b. Recombinant human interferon a-2b, like leukocyte interferon, has the following activities: antiviral, antitumor and immunomodulating, without being a toxic compound.
The active substance of Laferobion has antiviral, antitumor and immunomodulatory effects, while it is recombinant human interferon does not have toxic effects.
After the introduction of Laferobion, a whole cascade of reactions is triggered: protein synthesis, inhibition of proliferation, immunomodulating activity (through phagocytes, macrophages and lymphocytes) suppression of viral replication in infected cells. The maximum concentration of Laferobion is observed on average 4-10 hours after subcutaneous or intramuscular injection, the half-life is 2-3 hours, after intravenous administration, the maximum concentration is recorded after 30 minutes, and the half-life is approximately 2 hours.
Composition
Interferon is a recombinant human a-2b + auxiliary substance.
Indications
Complex therapy of infections caused by:
- herpes virus (genital herpes, herpetic lesions of the eyes, shingles, herpetic rashes on the skin);
- hepatitis B virus (medium and heavy forms);
- mixed infections (viral and bacterial), including in children under 1 month (influenza, ARVI, ARI);
- human papillomavirus (HPV).
Complex therapy of oncological diseases:
- melanoma of the skin and eyes;
- tumors of various localization (cancer of the ovary, kidney, bladder, breast);
- myeloma;
- Kaposi's sarcoma;
- other malignant tumors of different localization.
Complex therapy of multiple sclerosis.
Forms of release
Candles rectal.
Powder (lyophilizate) for the preparation of a nasal solution in ampoules of 100,000 IU (sometimes mistakenly referred to as droplets).
Powder (lyophilizate) for the preparation (dilution) of a solution for injections (injections in ampoules).
There are no other dosage forms, be it pills or capsules.
Instructions for use and how to use them
Candles
Candles Laferobion is applied rectally. Usually the course of treatment is 10 days. In case of papillomavirus infection, precancerous cervical diseases, bacterial, viral and mixed infections and urogenital mixed infections, sexually transmitted infections, one candle is usually prescribed one hour later. Laferobion 1.5 million IU every 12 hours.
Children Laferobion is prescribed as a part of complex therapy for a single candle Laferobion 150 thousand IU every 12 hours. The average course duration is 5 days.When treating ARVI, pneumonia of various etiologies and meningitis usually one course is enough. To treat infections caused by the Epstein-Barr virus, an increase in dosage and course duration is required.
Ampoules of nasal solution
Treatment with Laferobionum is most effective in prescribing it in the first days of the disease, with the appearance of initial symptoms. For the treatment of acute respiratory viral infections (including influenza) and mixed viral-bacterial infections, Laferobion is used in the form of inhalations, spray or by instillation into the nasal passages.
When instilled, the recommended dose is 5 drops of the drug (0.25 ml) with an activity of 50 thousand to 100 thousand IU in each nasal passage, every 60-120 minutes, but not less than 6 times a day, the course of treatment should be at least, 2-3 days.
Effective administration of Laferobion by inhalation, using an ultrasonic inhaler. For one inhalation (through the mouth and / or nose), it is necessary to dissolve 3 vials of the drug in 5 ml of water (sterile or boiled), inhalation twice a day.
For the treatment of children under the age of 1 month, the use of nasal turunds moistened with Laferobion is recommended, turuncas are introduced alternately in each nasal passage for 10-15 minutes.For instillation of the drug in children of this age group, Laferobion is recommended with an activity of 50 thousand IU for 2-3 drops in each nasal passage 4 to 6 times a day, the course of therapy is designed for a period of 3 to 5 days.
In order to prevent infection with SARS during epidemics or in contact with a sick person, it is recommended to instill or spray Laferobion with an activity of 50 thousand to 100 thousand in 1 ml, during the whole life of the threat of infection, 5 drops of the drug (0.25 ml) twice per day, the interval between administration of the drug should be at least 6 hours.
Dilution of lyophilizate Laferobion for nasal use
To get Laferobion with an activity of 50 thousand, it is necessary to dissolve the contents of the vial in 2 ml of sterile (distilled or boiled) water, with an activity of 100 thousand, in 1 ml of water. To obtain a homogeneous solution, shake the bottle thoroughly. Use the resulting solution for instillation into the nose (into both nostrils) according to the dosage regimen specified in the instructions.
Ampoules for injections
Solution for injection is intended for subcutaneous, intramuscular. Before use, dissolve the contents of the vial in 1 ml of water for injection.
For the treatment of acute hepatitis B (moderate or severe course), the following scheme of application of Laferobion is recommended: 1 million IU of the drug is administered twice a day for 5-6 days, then the dose is reduced to 1 million IU per day and injections are continued within 5 days, if necessary, the prolongation of the therapy goes to the introduction of 1 million IU twice a week, for another 14 days. The most effective is Laferobion when applied in the first 5 days of icteric period, the administration of the drug at a later date is less effective. It is not recommended to use the drug with a cholestatic variant of hepatitis or with the development of hepatic coma.
In chronic hepatitis B (active course), the appointment of Laferobion for 3-6 million IU is recommended three times a week, the course of therapy should last up to 24 weeks. At week 12, it is necessary to evaluate the effectiveness of the drug, if at this time there is no clinical improvement and a decrease in the HbeAg titer, the drug therapy should be discontinued.
In chronic hepatitis C, it is recommended that Laferobion be prescribed 3 million IU three times a week, and the course of therapy should last up to 24 weeks.After therapy with the drug for 1 month, it is necessary to assess the level of ALT, if the decrease of this marker is less than 50% of the baseline, the dose of Laferobion should be increased to 6 million. At week 12, it is necessary to evaluate the effectiveness of the drug if at that time there is no clinical and biochemical improvement, drug therapy should be discontinued.
Treatment of tick-borne encephalitis involves the introduction of 1-3 million IU twice a day for 10 days, after which they switch to maintenance therapy for 1-3 million IU every two days for 10 days.
In the treatment of cancer, the maximum possible doses of the drug (ie, those doses that the patient can take for a long time) are used. Laferobion has only a cytostatic effect, therefore it is necessary to use it after reaching remission or regression of the tumor focus.
In chronic myeloid leukemia, the use of Laferobion is recommended for 9 million IU daily until hematologic remission is achieved, then the maintenance dose is administered: 9 million IU three times a week.
With lymphocytic (hairy cell) leukemia, the use of laferobion3 million IU daily until hematologic remission is achieved, then go on to administer a maintenance dose of 3 million IU three times a week.
In renal cell carcinoma, it is recommended to use Laferobion for 18 million IU three times a week.
In malignant melanoma, the use of Laferobion for 18 million IU daily is recommended until complete or partial regression of metastases is achieved, and then a maintenance dose of 18 million IU is administered thrice a week.
With Kaposi's sarcoma, patients with AIDS recommended the use of Laferobion for 36 million IU daily for a long time, drug cancellation is possible with its intolerance or uncontrolled progression of the disease. After stabilization of the condition, it is recommended to switch to maintenance therapy for 18 million IU three times a week.
Side effect
- influenza-like syndrome (pain in muscles, joints, neck, back, eyes, headache, asthenia, chills);
- hypercalcemia;
- dehydration;
- lymphadenopathy;
- cachexia;
- edema (periorbital, genital organs);
- thirst;
- phlebitis;
- hypothermia;
- allergic reactions;
- dry skin;
- hemolysis;
- leukopenia;
- thrombocytopenia;
- hypochromic anemia;
- arrhythmia (more often extrasystole, sinus tachycardia or bradycardia);
- angina pectoris;
- cardiomegaly;
- cardiomyopathy;
- Raynaud's syndrome;
- arterial hypotension;
- pulmonary embolism;
- change in the level of thyroid hormones (hypothyroidism or hyperthyroidism);
- gynecomastia;
- hyperglycemia;
- dyspepsia;
- anorexia;
- gingivitis;
- change in taste;
- gastralgia;
- hepatitis (up to the hepatic coma);
- change in the level of liver enzymes;
- changes in the joints (arthritis, arthrosis, rheumatoid arthritis);
- pain in the bones;
- tendonitis;
- hyporeflexion;
- depression;
- disturbances in sleep, memory, thinking, attention, speech;
- paresthesia;
- extrapyramidal disorders;
- migraine;
- propensity to suicidal reactions;
- dizziness;
- delirium;
- emotional lability and aggressive reactions;
- ataxia;
- amenorrhea;
- impotence;
- dryness of the vagina;
- sexual deviations;
- sinusitis;
- dyspnea;
- rhinitis;
- unproductive cough.
Contraindications
- intolerance to the active substance (interferon) or any of the additional components of the drug;
- period of pregnancy;
- severe liver and kidney disease.
Application in pregnancy and lactation
Studies on pregnant women have not been conducted, so pregnancy is a contraindication to the appointment of Laferobion.
There is no data on the possibility of penetration of the drug into breast milk, so it is not recommended for women during lactation.
Use in children
Possible use in children (including infants and newborns) up to 1 month and older according to the dosage regimen specified above.
special instructions
The prepared solution can be stored for no more than a day, at a temperature of no more than 2-8 degrees Celsius.
During therapy with Laferobionum, alcohol is prohibited.
Drug Interactions
It is not recommended to assign Laferobion simultaneously with glucocorticosteroids, joint use with other drugs is not contraindicated.
Analogues of the drug Laferobion
Structural analogs for the active substance:
- Alfaferon;
- Wallferon;
- Interferon alfa-2b is a human recombinant;
- Interferon leukocyte human;
- Inferon;
- Lokferon.
Analogues for the pharmacological group (interferons):
- Avonex;
- Algeron;
- Altevir;
- Alfaron;
- Alfaferon;
- Betaferon;
- Vagiphereon;
- Viferon;
- Wallferon;
- Genfaxon;
- Genferon;
- Genferon Light;
- Herpferon;
- Hyaferon;
- Grippferon;
- Ingaron;
- Inter;
- Interferal;
- Interferon alfa-2 human recombinant;
- Interferon beta-1b human recombinant (rchifn-beta);
- Interferon leukocyte human;
- Intron A;
- Infagel;
- Inferon;
- Infibet;
- Kipferon;
- Layfferon;
- Lokferon;
- Ophthalmoferon;
- PegAtlevir;
- Pegasys;
- PegIntron;
- Peginterferon alfa-2b;
- Realdiron;
- EU Reaferon;
- Reaferon EU Lipint;
- Rebif;
- Ronbetal;
- Roferon A;
- SynnoWex;
- Extavia.